Metaphore Biotechnologies and Flagship Pioneering have entered a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management.
 
The collaboration is signed under the broader strategic partnership between Novo Nordisk and Flagship Pioneering to develop a portfolio of novel treatment approaches for cardiometabolic and rare diseases. Pioneering Medicines, Flagship’s in-house drug development and partnerships unit, is responsible for leading the broader partnership together with Novo Nordisk’s Bio Innovation Hub, an R&D unit designed to accelerate the development of therapeutics via co-creation partnerships.
 
Metaphore will work jointly with Pioneering Medicines and Novo Nordisk to advance the programs through foundational activities and preclinical development. After that point, Novo Nordisk could advance the programs into clinical studies.

Applying a Machine Learning Approach to Obesity Management

“Through our collaboration with Metaphore we will apply a novel machine learning approach to obesity management, an area that continues to need more innovation,” said Uli Stilz, Head of the Novo Nordisk Bio Innovation Hub. “Metaphore’s platform aims to mimic the interactions between molecules with impressive accuracy by capturing their natural dynamics at the point of interface, potentially leading to therapeutics that require infrequent dosing. Our strategic framework with Flagship Pioneering continues to illustrate the value of partnerships in bringing forward disruptive technologies for therapeutic areas with unmet need.”
 
The collaboration will leverage Metaphore’s MIMIC platform with the goal to design multitarget therapeutics targeting the GLP-1 receptor and related biology, to create scalable, long-acting agents that will require infrequent dosing.
 
“Working with Novo Nordisk is a significant opportunity to apply our MIMIC platform in one of the most exciting areas of drug development and with one of the most experienced drug development teams working in obesity,” said Lovisa Afzelius, Origination Partner at Flagship Pioneering and Co-Founder and CEO of Metaphore. “This collaboration could further validate our unique ability to program function into therapeutic molecules with the MIMIC platform to enhance efficacy, extend durability, and optimize manufacturing for a single therapeutic addressing multiple obesity-related targets, including but not limited to the GLP-1 receptor.”
 
Under the terms of the agreement, Novo Nordisk may pay up to $600 million in upfront, development, and commercial milestone payments, as well as tiered royalties on annual net sales of licensed products, to be shared between Metaphore and Pioneering Medicines. Novo Nordisk will also reimburse R&D costs and participate in a future financing round for Metaphore.

More Novo Nordisk News

Earlier this year, Catalent Inc., a global CDMO headquartered in New Jersey, and Novo Holdings, entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction.